Fulcrum PIONEER data reinforce pociredir differentiated profile, Wainwright says

Keeping a Buy rating on Fulcrum Therapeutics (FULC), H.C. Wainwright views the full 12-week data from the 20 mg cohort of the PIONEER study as encouraging and supportive of pociredir’s emerging differentiated profile, reinforcing its ability to drive clinically meaningful HbF induction with favorable tolerability. Collectively, the data strengthens the firm’s view that pociredir is demonstrating clinically meaningful biologic activity with a differentiated efficacy profile relative to other emerging HbF inducers, supporting advancement toward a potential registrational trial expected to initiate in the second half of 2026 pending FDA feedback. Wainwright has a Buy rating and a price target of $25 on the shares.